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1013-68 N-Terminal Brain Natriuretic Peptide: The New Gold 
Standard in Predicting Mortality in Patients With 
Advanced Heart Failure 
Roy S. Gardner. Faruk Ozalp, Andrew J. Murday, Stephen D. Robb, Theresa A. 
McDonagh. University of Glasgow, Glasgow, United Kingdom 
Background. Selection of patients for cardiac transplantation is difficult and has tradi- 
tionally relied upon assessing clinical status as well as parameters of LV dysfunction 
associated with an adverse outcome such as the left ventricular ejection fraction (LVEF), 
maximum oxygen uptake (VC& “ax) and more recently, composite scoring SyStSmS e.g. 
the heart failure suwival score (HFSS). Brain natriuretic peptide (BNP) is well established 
as an independent predictor of prognosis in mild to moderate chronic heart failure (CHF). 
However, the prognostic ability of NT-proBNP in advanced heart failure is unknown and 
no studies have compared NT-proBNP to standard clinical markers used in the selection 
of patients for transplantation. This study describes the prognostic ability of NT-proBNP 
and compares it to that of the LVEF, VC$ max and the HFSS in a coholt of patients 
referred for cardiac transplantation. 
Methods We prospectively studied 128 consecutive patients with advanced CHF 
referred for consideration of cardiac transplantation. Blood for NT-proBNP analysis was 
sampled at recruitment and patients followed up for a mean of 280 days. We report on 
the primary endpoint of all cause mortality and the secondary one of all Cause morlality or 
urgent cardiac transplantation. 
Results The median N-BNP was 1498pg/ml [inter-quartile range 544-38831. The only 
univariate and multivariate predictor of all cause mortality was an NT-proBNP level 
above the median value (R&5.0 [1.7-22.41, p=O.O02). The univariate predictors of all 
cause mortality or urgent cardiac transplantation were: a RVEF<median (RR=3), a 
HFSS<median (RR=3) and serum sodiumcmedian (RR=4.3) and NT-proBNPzmedian 
(RR=@. The only Independent predictors of all cause mortality or urgent cardiac trans- 
plantation were an NT-proBNP value>median (RR=6.9 [2.0-23.71. p=O.OOZ) and a serum 
sodium concentratkxxmedian value (RR=4.4 [l.l-9.71, p=O.O4). LVEF, VQ and HFSS 
were not independently predictive of mortality in this study. 
Conclusions. A single measurement of NT-proBNP in patients with advanced CHF can 
help to identify patients at the highest risk of death, and is a better prognostic marker 
than LVEF, VQ or HFSS. 
1013-69 Relationship Between Serial Measurements of N- 
Terminal Pro-Brain Natriuretic Peptide and Ambulatory 
Cardiac Filling Pressures in Outpatients With Heart 
Failure 
Frieder Braunschwelq, Astrid Fahrleitner, Stefano Ghio, Maurizio Manglavacchi, Parwis 
Fotuhi. Uta C. Hoppe, Mark Harrison, Cecila Linde. Karolinska Hospital, Stockholm, 
Sweden 
Background: Plasma levels of N-terminal pro brain natriuretic peptide (NT-proBNP) are 
thought to reflect the hemodynamic state and may be useful in the management of out- 
patients with chronic heart failure (CHF). We used an implanted hemodynamic monitor 
(IHM) to study the relationship between serial measurements of plasma NT-proBNP lev- 
els and ambulatory cardiac filling pressures. 
Methods: 13 pt with CHF (58 f 10 y; LVEF 24 + 8%; LVEDD 69 * 13 mm) with an IHM, 
(Chronicle@, Medtronic lnc) were included. The ambulatory right ventricular systolic pres- 
sure (RVSP) and estimated diastolic pulmonary altery pressure (ePAD) were sampled 
continuously and expressed as the 24 hour median preceding each blwd sample. Three 
to six blood samples for analysis of plasma NT-proBNP (ELISA, Biomedica, normal 
range < 250 fmollml) were taken in each patient with a minimum interval of two weeks in 
between. Intra-patient correlations between serial NT-proBNP measurements and the 
corresponding filling pressures were calculated using a random coefficient model (proce- 
dure Mixed in SAS). 
Results: NT-proBNP plasma levels were elevated in all cases (range 522-1696 fmollml) 
but varied largely between patients. Accordingly, the individual means of NT-proBNP and 
hemodvnamic parameters were not correlated (r=O.lZ and 0.13 for RVSP and ePAD 
respectively). However, serial measurements in the individual patients yielded significant 
positive intra-oat&t correlations between NT-!xoBNP and RVSP imedian r=0.71. 
p=O.O06) and ePAD (median r=O.71, p= 0.001). respectively. 
Conclusion: In outpatients with chronic heart failure, serial measurements of NT-proBNP 
in the same Individual correlate significantly with hemodynamic parameters and reflect 
changes of the hemodynamic state over time, despite a large variation of NT-proBNP 
plasma levels between patients. This finding supports the hypothesis, that serial mea- 
surements of NT-proBNP may be a useful tool for outpatient management in chronic 
heart failure. 
1013-70 Neurohumoral Changes as Markers of Progressive Left 
Ventricular Remodeling in Systolic Heart Failure: 
Results of the Neurohumoral Substudy of the 
Randomized Evaluation of Strategies for Left 
Ventricular Dysfunction (RESOLVD) 
Raymond T. Yan, Rizwan Afzal, Robert McKelvie, McMaster University and Hamilton 
Health Sciences, Hamilton, ON, Canada 
Background:Various neurohormones (NH) are reported as useful diagnostic markers of 
heart failure (HF) and have been shown previously to correlate with baseline left venttic- 
ular ejection fraction (LVEF) and volumes. However, the relationships between temporal 
changes in these NH and progressive cardiac remodeling in chronic HF have not been 
studied. 
Methods: We evaluated 677 subjects with baseline LVEF 28*10% (mean&D) enrolled 
in RESOLVD, a P-phase 3x2 factorial randomized study of the efficacy of candersartan at 
various doses and metoprolol in addition to enalapril in systolic HF. Serial changes in 
LVEF (1.8+6.9%). end-diastolic volume (EDV 18t60ml), and end-systolic volume (ESV 
9*53ml) measured by radionuclide ventriculography between baseline and end of phase 
II (week 42) wars correlated with time correspondent changes in brain natriuretic peptide 
(BNP), N-terminal proatrial natriuretic peptide (NBANP), angiotensin II, aldostsrone, 
endothelin I, norepinephrine and epinephrine. 
Results: Among all measured NH, only changes in BNP and Nt-ANP were significantly 
correlated with changes in EDV. ESV and LVEF consistently irrespective of study phase 
and therapy as summarized below: 
Pearson Co&i&m for Changes Between End of Phase II (week 42) and Baseline 
Pearson Coefficients: 
All subjects (N=677) 
‘P = 0.01 
“P < 0.0001 
Changes in ESV Changes in EDV Changes in LVEF 
BNP changes 
Nt-ANP Changes 
Angiotensin II Changes 
Aldosterone Changes 
Endothelin I Changes 
+ 0.24 ** + 0.24 ** - 0.18 ** 
+ 0.25 ** + 0.23 ** - 0.10 * 
- 0.03 - 0.04 + 0.01 
+ 0.03 + 0.06 - 0.07 
- 0.03 - 0.03 
O.&l 
Norepinephrine Changes + 0.02 + 0.04 - 0.03 
Epinephrine Changes - 0.02 - 0.03 0.02 
Conclusions In this shalt-term study, serial increases in BNP and Nt-ANP levels pre- 
dicted ongoing adverse LV remodeling evidenced by declining LVEF, increasing EDV 
and ESV. Serial measurements of these NH may serve as useful clinical markers for high 
risk HF patients in whom more aggressive therapy may be warranted. 
1013-71 Plasma Norepinephrine Predicts la-Year Survival in 
Patlents With Reduced Ejection Fractions From the 
Studies of Left Ventricular Dysfunction (SOLVD) 
Philip Jong. Michel F. Rousseau, Sylvie A. Ahn, Shrikant I. Bangdiwala, Claude R. 
Benedict, Salim Yusuf, M&taster University, Hamilton, ON, Canada 
Background: In the Studies Of Left Ventricular Dysfunction (SOLVD), plasma norepi- 
nephrine (PNE) was shown to predict in-trial survival among patients with reduced ejec- 
tion fractions. We examined whether PNE and other neurohormones would also predict 
long-term suwival during a post-trial follow-up of SOLVD. 
Methods: PNE (n = 730), plasma renin activity (n = 731), atrial natriuretic peptide (n = 
366), and arginine vasopressin (n = 364) were measured at baseline in subsets of 6797 
patients previously enrolled in SOLVD. Risk-adjusted suwival at 12 years after trial 
enrollment was compared between patients whose neurohormonal levels lied above and 
below the group median values. 
Results: PNE was the strongest neurohormonal predictor of 12.year swvival. After 
adjusting for age, sex, ejection fraction, cause of heart failure, functional class, treatment 
and trial assignments, PNE levels above the median of 409 pgiml were associated with a 
36% relative hazard increase in all-cause mortality (95% Cl 11 to 66%, p = 0.003) and a 
42% relative hazard increase in cardiac mortality (95% Cl 13 to 79%, p = 0.003), as com- 
pared with levels below the median (Figures). Increases in the levels of the other neuro- 
hormones were not predictive of all-cause mortality in the long term. 
Conclusfon: Elevated PNE remains a powerful and independent predictor of increased 
